文献速递肾癌与肾肿瘤

移植肾同种异体肾细胞癌的局灶消融治疗

Focal Ablative Therapy for Renal Cell Carcinoma in Transplant Allograft Kidneys.
PubMed 文献 · Urology · 2018-12-12

本研究回顾性分析了6例在移植肾同种异体肾中发生肾细胞癌并接受局灶消融治疗的患者。中位随访45个月,无患者需要透析,无局部复发,但1例出现淋巴结转移。结论认为局灶消融是保留肾单位可行的干预措施。

要点

  • 移植肾肾细胞癌局灶消融后中位随访45个月无局部复发。
  • 消融后无人需要透析,中位肌酐水平稳定。
  • 1例患者消融4年后出现淋巴结转移。

核心结论

  • 局灶消融治疗是移植肾肾细胞癌可行且保留肾单位的干预措施,中期随访结果支持其应用。

研究设计与样本

  • 回顾性病例系列研究,纳入2010年至2017年间在本机构接受局灶消融治疗的6例移植肾肾细胞癌患者。

主要发现

  • 肿瘤诊断距移植中位时间8年(范围1个月至8年),中位肿瘤大小3 cm。
  • 3例接受微波消融,1例经皮不可逆电穿孔,1例腹腔镜冷冻消融,1例开放冷冻消融。
  • 中位随访45个月(范围8至61个月),无患者出现局部复发。
  • 消融前中位肌酐1.65,消融后1年中位肌酐1.58,无患者需要透析。
  • 1例患者在消融后4年出现淋巴结转移,2例因其他原因死亡,死亡时移植肾功能正常。

临床怎么用

  • 对于移植肾肾细胞癌患者,局灶消融可作为保留移植肾功能的治疗选择。
  • 术后需定期监测肾功能和影像学以评估肿瘤复发及转移。

局限性

  • 样本量小(仅6例),为单中心回顾性研究,随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate outcomes after focal ablative therapy for renal cell carcinoma (RCC) in transplant allograft kidneys. METHODS: After institutional review board approval, patients with a history of RCC in a transplanted allograft kidney who underwent focal ablative therapy were identified. Complete chart reviews were performed and the relevant data were extracted for cumulative analysis. RESULTS: Six patients were treated with focal ablative therapy for RCC in a transplanted allograft kidney at our institutional between 2010 and 2017. Masses were diagnosed at a median of 8 years (range 1 month-8 years) after transplantation. Median mass size was 3 cm. Three patients were treated with microwave ablation, 1 with percutaneous irreversible electroporation, 1 with laparoscopic cryoablation, and 1 with open cryoablation. Median follow-up was 45 months (range 8-61 months). The median creatinine level was 1.65 before ablation and 1.58 1 year after ablation. No patients required dialysis after ablation. No patients developed local recurrence during the follow-up period. However, 1 patient developed lymph node metastases 4 years after ablation. Two patients died during follow-up of other causes. At the time of death both patients had functioning grafts. CONCLUSION: Focal ablative therapies are a feasible, renal-sparing intervention for the management of RCC in renal allografts at intermediate-term follow-up.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Gul ZG, Griffith JJ, Welch C, et al. Focal Ablative Therapy for Renal Cell Carcinoma in Transplant Allograft Kidneys. Urology. 2018. PMID: 30552936. doi:10.1016/j.urology.2018.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。